TRxADE HEALTH (Nasdaq:MEDS) - Cotización, noticias y análisis

Resumen de acción MEDS

TRxADE HEALTH, Inc. opera como empresa de tecnología de la información (TI) de servicios sanitarios en Estados Unidos.

MEDS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene menos de 1 año de cash runway

Los beneficios han disminuido un 47.7% al año en los últimos 5 años

Los accionistas han sido diluidos sustancialmente en el último año

No tiene una capitalización de mercado significativa ($9M)

+ 1 riesgos adicionales

Competidores de TRxADE HEALTH, Inc.

OneMedNet

NasdaqGM:ONMD

US$13.5m

HealthLynked

OTCPK:HLYK

US$15.1m

Healthcare Triangle

NasdaqCM:HCTI

US$5.9m

NantHealth

OTCPK:NHIQ

US$19.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for TRxADE HEALTH
Historical stock prices
Current Share Price	US$6.30
52 Week High	US$44.56
52 Week Low	US$3.69
Beta	1.93
1 Month Change	-38.48%
3 Month Change	44.14%
1 Year Change	30.76%
3 Year Change	-89.71%
5 Year Change	-84.09%
Change since IPO	-99.99%

Noticias y actualizaciones recientes

Recent updates

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

Jul 25

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Mar 30

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Nov 23

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Jul 29

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

Jun 16

SpartanNash and Bonum Health join hands to provide telemedicine services

Jun 07

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

May 22

Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Apr 28

Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Apr 01

Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

Feb 05

Rentabilidad de los accionistas

	MEDS	US Healthcare Services	Mercado US
7D	-5.4%	0.2%	2.0%
1Y	30.8%	-10.4%	22.3%

Rentabilidad vs. Industria: MEDS superó al sector US Healthcare Services , que obtuvo un rendimiento del -10.4% el año pasado.

Rentabilidad vs. Mercado: MEDS superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.

Volatilidad de los precios

Is MEDS's price volatile compared to industry and market?
MEDS volatility
MEDS Average Weekly Movement	48.8%
Healthcare Services Industry Average Movement	9.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de MEDS ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MEDS ha aumentado de 33% a 49% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2010	8	Suren Ajjarapu	www.trxadehealth.com

TRxADE HEALTH, Inc. opera como empresa de tecnología de la información (TI) de servicios sanitarios en Estados Unidos. La empresa se centra en la digitalización de la experiencia de la farmacia minorista mediante la optimización de la adquisición de medicamentos, la prescripción de viaje, y el compromiso del paciente; y diseña, desarrolla, posee y opera un mercado basado en la web de empresa a empresa. También distribuye medicamentos con receta, dispositivos médicos y medicamentos sin receta a farmacias y clínicas médicas; y ofrece transparencia de precios, capacidades de compra y otros servicios de valor añadido, así como servicios de telesalud.

Resumen de fundamentos de TRxADE HEALTH, Inc.

¿Cómo se comparan los beneficios e ingresos de TRxADE HEALTH con su capitalización de mercado?
Estadísticas fundamentales de MEDS
Capitalización bursátil	US$8.87m
Beneficios(TTM)	-US$13.72m
Ingresos (TTM)	US$8.27m

1.1x

Ratio precio-ventas (PS)

-0.6x

Ratio precio-beneficio (PE)

¿Está MEDS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MEDS
Ingresos	US$8.27m
Coste de los ingresos	US$5.67m
Beneficio bruto	US$2.60m
Otros gastos	US$16.32m
Beneficios	-US$13.72m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-9.76
Margen bruto	31.41%
Margen de beneficio neto	-165.86%
Ratio deuda/patrimonio	1,208.6%

¿Cómo se ha desempeñado MEDS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción MEDS

Recompensas

Análisis de riesgos

Competidores de TRxADE HEALTH, Inc.

NasdaqGM:ONMD

US$13.5m

OTCPK:HLYK

US$15.1m

NasdaqCM:HCTI

US$5.9m

OTCPK:NHIQ

US$19.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

Recent updates

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

Price target decreased to US$3.25

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

TRxADE Health prices of $1.8M stock offering

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE Health launches next day delivery services via Trxade prime plus program

TRxADE Health proposes public stock offering

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Consensus EPS estimates fall by 19%

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.92

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

Consensus EPS estimates fall by 54%

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Price target decreased to US$7.50

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Price target decreased to US$8.75

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

SpartanNash and Bonum Health join hands to provide telemedicine services

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

Price target decreased to US$10.00

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)